Boston, MA — Ginkgo Bioworks announced that its Ginkgo Datapoints offering has entered into an agreement with Lilly TuneLab, an artificial intelligence and machine learning drug discovery platform created by Eli Lilly and Company.
Under the agreement, Ginkgo Datapoints will provide discovery data generation services to companies participating in TuneLab, including small molecule developability testing, such as ADME, and antibody developability testing.
TuneLab provides participating biotechnology companies with access to AI and machine learning drug discovery models trained on decades of Lilly research data.
“The combination of Ginkgo’s automation and TuneLab’s collaboration platform aims to accelerate next-generation therapeutic development across the industry. TuneLab is attracting many biotechs who benefit from access to powerful predictive models that are constantly improving via contributions from the network. Layering on Ginkgo’s ability to quickly generate high-quality, AI-ready datasets at any scale, we believe TuneLab participants will be able to close the loop between digital design and biological reality faster than ever before,” said John Androsavich, Ph.D., General Manager at Ginkgo Datapoints.
Ginkgo said its laboratory automation capabilities will allow TuneLab participants to run experiments and receive results in machine learning-ready formats that can be incorporated into TuneLab’s predictive models.
The company said standardized assay protocols across the TuneLab ecosystem are expected to help AI and machine learning models learn more efficiently. New TuneLab members will also be able to submit data generated by Ginkgo Datapoints to access additional platform model benefits.
The agreement expands Ginkgo Datapoints’ work in providing data generation services designed for AI and machine learning applications in drug discovery.
Lilly TuneLab is part of Lilly Catalyze360, which also includes Lilly Ventures, Lilly Gateway Labs and Lilly ExploR&D. The initiative supports biotechnology companies through access to capital, laboratory space, technology and research and development capabilities.
